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Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is an autosomal 
dominant disorder caused by C-terminal frameshift muta-
tions in the TREX1 gene,1 which encodes the ubiquitously 
expressed Trex1 (three prime repair exonuclease 1) protein.1,2 
The mechanisms underlying the cause of RVCL-S, however, 
are unknown. RVCL-S is a systemic progressive small ves-
sel disease with middle-age severe symptomatology and 
decreased life expectancy, characterized by vasculopathy in 
various organs, most pronounced in retina, kidney, and brain, 
with white matter lesions and intracerebral mass lesions.3–6 
Patients with RVCL-S report more often migraine (generally 
without aura) and have increased risk for ischemic stroke, 
both suggesting vascular involvement. Pathological studies 
revealed thicker endothelial cells with increased vesicles 
and coarse cytoplasm, and thicker, multi-laminated, base-
ment membranes of endothelial cells.5 Hence it has been 
hypothesized that the endothelium of small vessels, partic-
ularly in highly vascularized organs, is affected in RVCL-S. 
Endothelial dysfunction (impaired endothelium-dependent 
vasodilation and endothelial cell damage),7 which has been 
proposed as disease mechanism for the vascular phenotype 
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seen in stroke and migraine, was also shown to underlie 
RVCL-S in patients.4
Although patients with RVCL-S are heterozygous for the 
TREX1 mutation, here we investigated transgenic homozy-
gous RVCL-S knock-in (KI) mutant mice that express a trun-
cated Trex1 protein (similar to what is seen in patients with 
RVCL-S).1,5 The mutant mice express a truncated mouse pro-
tein (with the endogenous regulation of gene expression still 
intact), which is slightly different from the existing human-
ized RVCL-S mouse model in which the human cDNA bear-
ing the same V235fs mutation was introduced in exon 2 of 
TREX1.8 Here we assessed whether homozygous RVCL-S 
KI mice have pathological features seen in patients with 
RVCL-S, such as a reduced life expectancy and a vascular 
phenotype (as assessed by functional vascular measurements 
and induction of experimental stroke).
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Experimental Animals
Homozygous transgenic RVCL-S KI and wild-type (WT) litter-
mate mice of different age groups (3–6, 12–14, and 20–24 months) 
were used. As the heterozygous mutants show a normal survival 
(Figure 1), we focused on a comparison between the homozygous 
mutant and WT mice. For the generation of the mutant mice, a tar-
geting construct was used by which a frameshift mutation was intro-
duced at amino acid position 235 of the Trex1 protein, resulting in 
a truncated protein as observed with the most prevalent RVCL-S 
mutation in patients (Methods and Figure I in the online-only Data 
Supplement).1,5 Homozygous mutant and WT mice were generated 
by interbreeding heterozygous mice. For the stroke experiments, 
only male mice were used. For the in vivo and in vitro vascular 
characterization, results of both sexes were pooled because no sex 
difference was detected. Animals were randomized (flip of a coin) 
for surgical procedure, and researchers were blinded for genotype 
during experimental and analyses procedures. Animals were housed 
in a temperature-controlled environment with food and water ad lib-
itum. All animal experiments were approved by the local commit-
tee for animal health, ethics and research of the Leiden University 
Medical Center.
Survival Analysis
Survival in naive WT and homozygous RVCL-S KI mice was 
assessed in animals who, at 2 months, were randomly assigned to one 
of the age groups (3–6, 12–14, and 20–24 months) to be included in 
the experimental stroke studies (n=97). Mice were censored for anal-
ysis when they reached the age of inclusion for the stroke experiment. 
In addition, data of 51 heterozygous animals, which were not used in 
experiments, were added to the survival analysis.
In Vivo Microvascular Characterization
Microvascular characteristics were assessed in vivo using postocclu-
sive reactive hyperemia (PORH) measurements of the hind leg with 
laser Doppler flowmetry (PeriFlux System 5000, Perimed, Järfälla-
Stockholm, Sweden). Twenty-four hours before dermal blood flow 
measurements, the hair of the left hind leg was removed with hair 
removal cream (Veet, ReckittBenckiser, Inc, Berkshire, United 
Kingdom). On the day of measurement, mice were anesthetized using 
4% isoflurane/O2 ventilation and kept on a heating pad regulated by a 
rectal thermometer (FHC, Inc, Bowdoin, ME) to maintain body tem-
perature at 36.7±0.3°C. After a 5-minute equilibration time period, 10 
minutes of baseline perfusion was recorded. Subsequently, the hind 
leg circulation was occluded for 2 minutes with a tourniquet. After re-
lease of the tourniquet, blood flow was monitored until return to base-
line blood flow (maximally 10 minutes). The area under the curve and 
PORH peak were used as readout measures. After the experimental 
procedure, mice were euthanized using decapitation, where the aorta 
was collected for in vitro measurements.
In Vitro Macrovascular Characterization
Macrovascular characterization was performed in vitro by mounting 
segments of the mouse aorta (inner diameter 0.5–1 mm) in Mulvany 
myographs with separated 6-mL organ baths9 containing carboge-
nated (5% CO2 and 95% O2) Krebs-Henseleit buffer solution (in mM: 
NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, H2PO4 1.2, NaHCO3 25 
and glucose 8.3; pH 7.4) at 37°C. Tension was normalized to 90% of 
the estimated diameter at 100 mm Hg of transmural pressure. A ref-
erence contractile response of vessel segments was determined with 
100 mmol/L KCl. For the acetylcholine and sodium nitroprusside 
(SNP) concentration-response curves, aorta segments were precon-
tracted with the thromboxane A2 analog U46619 (10–100 nmol/L). 
Relaxant effects of acetylcholine (endothelium-dependent) and SNP 
(endothelium-independent) and contractile effects of 5-hydroxytryp-
tamine were examined by cumulative application of increasing con-
centrations of drug.
Transient Middle Cerebral Artery Occlusion Model
Mice were anesthetized using isoflurane (3% induction, 1.5% 
maintenance) in 70% pressurized air and 30% O2. Carprofen 5 
mg/kg, SC (Carporal, 50 mg/mL; AST Farma B.V., Oudewater, 
the Netherlands) was administered before surgery for pain relief. 
During surgery, the mouse body temperature was maintained at 
36.7±0.3°C as described above. Experimental stroke was induced 
using the transient middle cerebral artery occlusion (tMCAO) 
model.10 A silicone-coated nylon monofilament (7017PK5Re; 
Doccol cooperation, Sharon, MA) was introduced into the internal 
carotid artery, via an incision in the common carotid artery, to 
block the middle cerebral artery (MCA) at its origin for 30 minutes. 
Cerebral blood flow in the MCA territory was measured using laser 
Doppler flowmetry (PeriFlux System 5000; Perimed) and calcu-
lated as %-measure of baseline. In a subset of animals, tcCO2 was 
measured (TCM4 CombiM monitor with accompanying software 
version 3.0; Radiometer Medical ApS, Brønshøj, Denmark) to con-
firm physiological stability during surgery (data not shown). After 
surgery, the animal was placed in a temperature-controlled recovery 
incubator (V1200; Peco Services Ltd, Brough, United Kingdom) 
maintained at 33°C for 2 hours, with easy access to food and water. 
Postprocedural observation was performed twice daily.
Figure 1. Survival curves from wild-type (WT), heterozygous (Het), and ho-
mozygous (Hom) retinal vasculopathy with cerebral leukoencephalopathy 
and systemic manifestations (RVCL-S) knock-in (KI) male mice. At 2 mo, 
Hom mutant and WT mice were randomly assigned to one of the 3 age 
groups for experimental stroke surgery. Mice reaching the age of surgical 
inclusion were censored from the analysis. WT (n=45, gray line), Het RVCL-
S KI (n=51, black dotted line), and Hom RVCL-S KI mice (n=52, black 
line). Vertical bars along curves represent censored animals. WT and Het 
survival curves were not significantly different. *P<0.05 indicates statistical 
significance between WT and Hom RVCL-S KI mice.
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Magnetic Resonance Imaging
Animals were scanned using a small animal 7T MRI system 
(Pharmascan, Bruker BioSpin, Ettlingen, Germany) under isoflurane 
anesthesia. A Multi Slice Multi Echo sequence protocol was run with 
repetition time/echo time of 4.000 ms/9 ms, 20 echoes, 2 averages, 
matrix 128×128, field of view of 2.50 cm, bandwidth 59 523.8 Hz, 
slice thickness of 0.5 mm, and 16 slices (no gap). Quantitative T2 
maps were calculated using Paravision 5.1 software (Bruker BioSpin). 
Scans were performed at 4, 24, and 48 hours after tMCAO surgery. 
An in-house developed automated software pipeline11 was used to 
calculate infarct sizes. If automated segmentation showed artifacts, 
for example, due to wrapping, small manual corrections were made, 
or scans were excluded due to technical failure.
Behavior Analysis
Behavior analyses were performed directly before magnetic resonance 
imaging measurements, that is, before and after (at 4, 24, 48 hours, 
and 5 days) tMCAO surgery. During behavioral tests, mice were vid-
eotaped, and blinded videos were analyzed after completion of the 
experiments. Neurological deficit scores were measured on a 56-point 
scale.12,13 The score involved general and focal deficits, where 0 re-
flected no deficits, and 56 reflected the poorest. Categories concerning 
general appearance and performance included fur (0–2), ears (0–2), 
eyes (0–4), posture (0–4), spontaneous activity (0–4), and epileptic 
behavior (0–12). Concerning the focal deficits a score was stated for 
body asymmetry (0–4), gait (0–4), climbing on a surface inclined at 
45° (0–4), circling behavior (0–4), front-limb symmetry (0–4), com-
pulsory circling (0–4), and whisker response to light touch (0––4).
Vessel Anatomy
A subset of mice was used for vessel anatomy analysis.14,15 In brief, 
mice were euthanized using CO2 and transcardially perfused using 2.5 
mL PBS with 50 μL heparin (Heparine natrium 5000 I.U./mL; LEO 
Pharma B.V., Amsterdam, the Netherlands) and 2.5 mL ink mixture 
(ratio 1:9, Herlitz stempelfarbe ink and Pelikan Scribtol ink; Pelikan 
Vertriebsgesellschaft mbH & Co. KG, Hannover, Germany) at a rate of 
3 mL/min, preheated to 37°C. Brains were removed, photographed, and 
post-fixated in fresh 4% paraformaldehyde. Vessel anatomy was scored 
as the number of anastomoses between MCA and anterior cerebral ar-
tery, distance between midline, and the anastomotic line at 2, 4, and 
6 mm from anterior and diameter of the main vessels of the circle of 
Willis (MCA, anterior cerebral artery, internal carotid artery, posterior 
cerebral artery, basilar artery, and posterior communicating artery). Pial 
anastomoses were defined as the narrowest part of the vessel or halfway 
between the nearest branch points of the anterior and the MCA, local-
ized by tracing the peripheral branches of these major vessels.
Statistical Analyses
All statistical analyses were performed in SPSS software (SPSS sta-
tistics 23, IBM Corporation, Armonk, NY). Survival analyses were 
performed using the log-rank (Mantel-Cox) test, and Cox univariable 
regression analyses were done to calculate the hazard ratio. Animals 
who reached the inclusion age of the experiment were censored in the 
analyses. The PORH results were expressed as relative values com-
pared with baseline and included the area under the curve (AUC) and 
the maximal hyperemia response (E
max
), expressed as mean±SEM. 
Vascular relaxant responses to acetylcholine and SNP were expressed 
as the percentage of contraction induced by 10 to 100 nmol/L 
U46619. Data for the vascular responses to 5-hydroxytryptamine were 
expressed as percentage of the contractile response to 100 mmol/L 
KCl. Both the in vivo and in vitro data were analyzed using univar-
iate ANOVA followed by Bonferroni post hoc tests. Outcome values 
were expressed as mean±SEM. Infarct volume and neurological def-
icit scores were compared between genotypes using marginal mixed 
model analyses (data are shown as estimated marginal means±SD). 
Survival analyses post-surgery were performed using the log-rank 
(Mantel-Cox) test. Group comparison concerning vessel diameter and 
anastomotic distance were analyzed using multivariate ANOVA with 
discriminant function analysis post hoc test. Absence of the posterior 
communicating artery was analyzed using Pearson χ2 (2-sided Fisher 
exact) test, and mean pial number of anastomoses were analyzed with 
a t test. P<0.05 indicates statistical significance.
Results
Increased Mortality in RVCL-S KI Mice
Homozygous RVCL-S KI mutant mice showed increased mor-
tality compared with WT controls: 16 (31%) mutant versus 4 
(9%) WT mice died during the observation period presurgery 
(P=0.03 with hazard ratio, 3.14 [95% CI, 1.05–9.39]). The 
increased mortality in the mutant mice compared to WT mice 
was apparent from 9 months of age (Figure 1). Heterozygous 
mutant mice did not show a reduced lifespan (P=0.55 with 
hazard ratio, 1.25 [95% CI, 0.60–2.59]; Figure 1). Therefore, 
only homozygous mutants were investigated in subsequent 
functional experiments. Postmortem examination, although sub-
optimal because considerable organ deterioration had occurred 
at the time of tissue examination, did not reveal a macroscopic 
cause of death (data not shown). Postmortem examination also 
did not show signs of brain atrophy, neither in the heterozygous 
nor the homozygous mutants, but also here the analysis was not 
reliable due to organ deterioration (data not shown). Finally, 
basic histological hematoxylin and eosin staining analyses of 
various organs (eg, eye, kidney, skin, liver, brain) of the homozy-
gous and heterozygous mutant mice did not reveal any obvious 
abnormalities (data not shown). In contrast with patients with 
RVCL-S,5 we observed no structural abnormalities in endothe-
lial cells or the basement membrane of the mutant mice. It re-
mains unclear whether this is because these disease features are 
not captured in the mouse model or whether these features need 
longer time to develop than the 2-year maximal age of a mouse.
Reduced In Vivo Microvascular Reactivity in  
RVCL-S KI Mice
Compared with WT, the RVCL-S KI mice showed a signifi-
cantly lower area under the reactive hyperemia curve across 
all age groups (F[1, 60]=5.1, P=0.03; Figure 2A). The max-
imal reactive hyperemia responses, however, were compa-
rable between genotypes (Figure 2B). Baseline dermal blood 
flow and time to maximum value were also similar between 
genotypes (data not shown).
Increased In Vitro Macrovascular Reactivity in  
RVCL-S KI Mice
No significantly different contraction reaction to 100 mmol/L 
KCl was seen between both genotypes. Instead, the concen-
tration-response curve to acetylcholine showed statistically 
significantly attenuated relaxant responses in 20- to 24-month-
old RVCL-S KI mice compared with WT mice (E
max
: 65±6% 
versus 37±8%, respectively, P=0.01), but not in mice of other 
age groups (Figure 2C). No genotypic difference was observed 
in the response to SNP or 5-hydroxytryptamine (Figure 2C).
Increased Susceptibility to Experimental Stroke 
With Worse Outcome in RVCL-S KI Mice
Overall, infarct volume was higher in RVCL-S KI compared 
with WT mice (P=0.02), with a significant effect of age 
D
ow
nloaded from
 http://ahajournals.org by on January 15, 2020
Mulder et al  Mortality and Vascular Phenotype in RVCL-S Mice  303
(P=0.02) and time after surgery (P<0.001). The effects were 
mainly driven by the increased infarct volume in RVCL-S 
KI mice at the age of 12 to 14 months (at 4 hours: RVCL-S 
KI: 60.4±5.4 versus WT: 39.8±4.8 mm3, P=0.007; 24 hours: 
RVCL-S KI: 84.3±9.5 versus WT: 52.9±7.8 mm3, P=0.01; 48 
hours: RVCL-S KI: 114.0±13.3 versus WT: 58.1±10.7 mm3, 
P=0.03; Figure 3). There was no significant genotypic differ-
ence in cerebral vessel anatomy (Figure II and Table I in the 
online-only Data Supplement). The overall neurological def-
icit score was worse in RVCL-S KI mice compared to WT for 
all age groups (P=0.002; Figure 4A). This effect was mainly 
driven by the 12- to 14-month-old group. In that age group 
neurological deficit scores was worse in RVCL-S KI than 
WT after surgery for an extended period of time (at 4 hours: 
RVCL-S KI: 29.3±3.4 versus WT: 11.1±2.9, P<0.001; 24 
hours: RVCL-S KI: 24.9±3.4 versus WT: 9.9±2.7, P=0.001; 48 
hours: RVCL-S KI: 28.5±3.8 versus WT: 10.0±2.6, P<0.001; 
5 days: 24.2±3.7 versus 7.5±2.4, P=0.001), whereas there was 
no difference before surgery (presurgery: RVCL-S KI: 0.6±0.4 
versus WT: 0.5±0.2, P=0.20). Mortality within 5 days after 
stroke onset was also increased in the 12- to 14-month-old 
group (RVCL-S KI: 7 [8%] versus WT: 4 [25%], P=0.04), an 
effect also present in the 20- to 24-month-old group (RVCL-S 
KI: 8 [57%] versus WT: 2 [13%], P=0.02); the young age 
group only showed a nonsignificant trend (RVCL-S KI: 4 
[57%] versus WT: 2 [33%]). There were no differences in 
basic parameters such as body weight (Table II in the online-
only Data Supplement) or activity levels (determined from 
presurgery analyses; Figure 4) between mutant and WT mice 
that could explain the difference in age-related survival.
Discussion
Here, we investigated whether RVCL-S KI mice, which ex-
press a truncated mouse Trex1 protein that mimics the trun-
cated protein seen in patients with the RVCL-S V235fs 
mutation,1,5 exhibit features in line with the phenotype of 
patients with RVCL-S. We demonstrated that homozygous 
RVCL-S KI mice have (1) a shorter life expectancy, (2) a 
vascular phenotype, as evidenced by abnormal PORH (mi-
crovascular characterization; in vivo in hind leg) and acetyl-
choline-induced relaxant (macrovascular characterization; 
in vitro in aortic segments) responses, and (3) an increased 
susceptibility to experimental stroke with a worsened out-
come. Except for outcome measures of experimental stroke, 
the other features can be considered spontaneous phenotypes. 
Except for signs of abnormal microvascular responses that 
were already observed from a young age (3–6 months), all 
other abnormalities were only observed in old mice, that is, 
in mice of 12 to 14 months and 20 to 24 months. Our study in 
mice is relevant because it is not understood how vasculopa-
thy, at middle-age, is brought about in patients with RVCL-S 
and how it is related to the lower life expectancy and increased 
risk for ischemic stroke.3–6 Similar to earlier observations in 
patients with RVCL-S, our data point to decreased functional 
endothelial responses in mice. In patients, this is exemplified 
by reduced flow-mediated dilatation responses,4 and in mice 
Figure 2. Microvascular and macrovascular characterization of wild-type (WT) and homozygous retinal vasculopathy with cerebral leukoencephalopathy and 
systemic manifestations (RVCL-S) knock-in (KI) mice. In vivo microvascular characterization using postocclusive reactive hyperemia (PORH) measurements 
of the hind leg with the area under the reactive hyperemia curve (A) and maximal reactive hyperemia (B) responses for WT and RVCL-S KI mice of the 3 age 
groups (3–6, 12–14, and 20–24 mo). *P<0.05 indicates a statistical significant difference between RVCL-S KI and WT mice across all age groups. Number of 
animals is indicated within each bar. C, In vitro macrovascular characterization of isolated aortae obtained from WT (gray circles) and homozygous RVCL-S 
KI (black squares) mice. Panels depict concentration-response curves to acetylcholine (ACh, n=7–16), sodium nitroprusside (SNP, n=7–17), and serotonin 
(5-hydroxytryptamine [5-HT], n=5–15). *P<0.05 indicates statistical significance for attenuated relaxant responses to ACh in 20- to 24-mo-old RVCL-S KI mice 
compared with WT mice. AU indicates arbitrary units; AUC, area under the curve; DBF, dermal blood flow; M, molar; m, months; and Max, maximal.Dow
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by reduced blood flow after PORH across all investigated ages 
and by reduced macrovascular relaxant responses to the endo-
thelium-dependent vasodilator acetylcholine.
RVCL-S KI Mice Have a Vascular Phenotype
This study is the first to show a vascular phenotype in RVCL-S 
KI mice. The results of the in vivo PORH experiments point 
towards a microvascular dysfunction, with a decreased AUC of 
the PORH but a normal maximal PORH peak. As the effect was 
seen in all age groups, it shows that a vascular phenotype is de-
veloping already before the mortality and increased stroke sus-
ceptibility become apparent. The PORH response16 represents 
an interplay between multiple vasodilation pathways, such 
as the endothelium-derived hyperpolarizing factor pathway17 
(which is characterized by the AUC) and the release of neuro-
peptides from perivascular nerves during the hyperemia peak 
(which is characterized by the maximal hyperemia response 
[E
max
]).18 Notably, in vitro examinations of macrovasculature 
showed abnormal endothelial function in response to acetyl-
choline but only in very old RVCL-S KI mice. The decreased 
relaxant response to acetylcholine seems because of diminished 
endothelial function, as responses to the endothelium-indepen-
dent NO donor SNP were normal in RVCL-S KI mice of the 
same age category. As mentioned above, the in vivo PORH AUC 
data suggest involvement of an affected endothelium-derived 
hyperpolarizing factor pathway response. Endothelium-derived 
hyperpolarizing factor acts as vasorelaxant and is known to 
act in microvessels rather than in larger vessels.19,20 Thus, the 
results of our in vitro macrovascular studies are not in contrast 
with the microvascular PORH results. Testing the natural ligand 
5-hydroxytryptamine21 showed no abnormal vasoconstrictive 
response in RVCL-S KI mice, although concentration-response 
curves tended to be lower in the 12- to 14- and 20- to 24-month-
old groups compared with WT mice.
Increased Ischemic Vulnerability in RVCL-S  
KI Mice
The vascular dysfunction seen in RVCL-KI mice may be the 
underlying cause of increased stroke risk in patients with 
RVCL-S. Therefore, we investigated whether RVCL-S KI 
mice had a worse stroke outcome. Although the infarct area is 
still evolving days to weeks after tMCAO, we used 48 hours as 
final magnetic resonance imaging readout point since infarct 
size on T2-weighted magnetic resonance imaging is maxi-
mized at 48 hours post-tMCAO.22 An overall increased infarct 
volume was observed in RVCL-S KI mice, compared with 
WT, albeit driven by the 12- to 14-month-old group. Given 
the decreased survival in the very old mutant mice, one can 
envisage that no genotypic difference in infarct volume was 
seen in the 20- to 24-month-old group because mutant mice 
that are most affected had already died before reaching the 
age of inclusion. Endothelial dysfunction was shown to lead 
to a procoagulatory, proinflammatory and proliferative state, 
which predisposes to atherosclerosis and increases stroke 
risk,7 but it remains to be researched whether this mechanism 
explains the increased infarct size in RVCL-S KI mice. In 
Figure 3. Infarct volume in wild-type (WT) and homozygous retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-
S) knock-in (KI) male mice. A, Example traces of automated stroke segmentation in T2-weighted magnetic resonance imaging (MRI) images at 24 h after 
infarct induction in 12- to 14-mo-old WT and RVCL-S KI mice. B, Stroke volumes at 4, 24 and 48 h after infarct induction in WT and RVCL-S KI mice of 
the 3 age groups (3–6, 12–14, and 20–24 mo; estimated marginal mean±SD), *P<0.05 indicates a statistically significant difference between 12- to 14-mo-
old RVCL-S KI and WT mice for each individual time point. Number of animals is indicated within each bar. Numbers can vary due to death of the animal 
or technical failure of the MRI scan. h indicates hours; and m, months.Dow
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future experiments, this should be investigated using electron 
microscopy for in-depth morphological examination to un-
cover the possible presence of subtle lesions of the brain en-
dothelium. There remains the, in our view unlikely, possibility 
that thrombus formation in the vessel after tMCAO may have 
influenced infarct outcome, as we have no a priori reason to 
assume that thrombus formation would be different between 
mutant and WT mice; although this, admittedly, has not been 
demonstrated, which would require the use of different meth-
odology than used in the present study.
There are other striking differences for the various age 
groups when considering infarct size and outcome. Not find-
ing a genotypic effect in young mice may be a reflection that 
the pathology has not advanced enough, although in vivo mi-
crovascular reactivity was already abnormal at that age. As 
alternative explanation, a genotypic effect may be masked 
by the seemingly unusually large stroke volume in the re-
spective WT mice, as volumes in WT mice from that age 
analyzed in our lab usually are 5% to 20% smaller (previ-
ously published data11).
It is even more surprising that mutant mice of 20-24 
months have a worse outcome after tMCAO but no increased 
infarct size. One plausible explanation may be inclusion bias. 
Because animals with large infarcts have a higher a priori 
chance of dying within 48 hours from infarct induction, mice 
that do survive tend to have smaller infarcts. Apparently, the 
mutant mice that could be included still exhibit mutation-
associated pathology, as reflected by the increased mortality. 
Such underlying pathology may also explain why a total of 
50% of the 20- to 24-month-old RVCL-S KI mice (compared 
with 15% of the WT group; Figure 1) had already died be-
fore scheduled surgery. Of relevance, WT aged male mice (and 
rats) have smaller infarct volumes,23 but worse functional out-
come,24,25 when compared with young animals. It remains en-
igmatic why aged male mice have a decreased infarct size.26,27 
Aged vessels may have undergone morphological and patho-
logical changes,28 such as structural alterations in the vessel 
wall, atherosclerosis and vessel wall calcification,29,30 small 
vessel disease,31 and a reduced impairment of poststroke syn-
aptic plasticity.27,32
RVCL-S Phenotype in Mice Versus Humans
Although the truncated protein product in our KI mouse is 
very similar to the human canonical TREX1 frameshift 
product, one always needs to be cautious when extrapolat-
ing data from transgenic mouse models to human disease. 
Although RVCL-S in humans is an autosomal dominant dis-
order, the presence of 1 mutated allele causes disease; in our 
experiments, we focused on homozygotes mice instead to in-
crease chances of capturing disease aspects by doubling the 
genetic load. It is not uncommon to focus investigations on 
homozygous mutant mice first as the lifespan in mice (max-
imal ~2 years) is much shorter than in humans, so a mutation 
has less time to exert its effect.
In humans, RCVL-S is characterized by various structural 
abnormalities, foremost the vasculopathy of the retina and 
Figure 4. Behavior analysis after infarct induction in wild-type (WT) and homozygous retinal vasculopathy with cerebral leukoencephalopathy and systemic 
manifestations (RVCL-S) knock-in (KI) male mice. A, Neurological deficit score (NDS; estimated marginal mean±SD) for WT SHAM surgery and WT and 
RVCL-S KI post–transient middle cerebral artery occlusion (tMCAO) and (B) survival curves at 4, 24, 48 h and 5 days after tMCAO or SHAM surgery in WT 
(continuous line) and RVCL-S KI mice (discontinuous line) of the 3 age groups (3–6, 12–14, and 20–24 mo). *P<0.05 indicates a statistically significant differ-
ence (A) between 12- to 14-mo-old RVCL-S KI and WT mice for NDS and (B) between RVCL-S KI and WT mice concerning survival post-surgery. d indicates 
days; h, hours; and m, months.Dow
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other organs, microinfarcts, and white matter lesions.5,6 A basic 
histological analysis of the eye and other organs in our mu-
tant mice did not reveal such abnormalities, even not in mice 
that were far older than 12 months. This can be regarded as a 
shortcoming of our model, but this disease feature may not be 
captured because of the shorter lifespan of a mouse. Not find-
ing histological abnormalities in our mutant mice is in accord-
ance with findings in a previously described RVCL-S mouse 
model,8,33 that also expresses V235fs-truncated, albeit human, 
Trex1 protein. In that model, DNase activity, a hallmark of 
Trex1, was maintained in truncated protein.33 Both heterozy-
gous and homozygous mutants were reported to be grossly 
normal with no signs of tissue inflammation; the mutant mice 
did exhibit striking elevations of autoantibodies against non-
nuclear antigens in the serum.33 Of note, the authors did not 
report the decreased survival phenotype, likely because they 
did not investigate very old mice. We would consider both 
RVCL-S mouse models equally relevant and having multiple 
transgenic models will allow replication in separate models.
RVCL-S is considered a small vessel disease.5 Abnormal 
functionality of the microvasculature, exemplified by the ab-
normal PORH response, was observed in mutant mice already 
of young age. Moreover, in the stroke experiments, outcome 
(as in human ischemic stroke) is influenced by the status of the 
microvasculature bed. Both types of experiments show that 
abnormal functionality of the microvasculature is captured 
in our mouse model. We recently found that functional en-
dothelial responses were decreased in patients with RVCL-S, 
while microvascular responses to capsaicin were normal (ana-
lyzed using flow-mediated vasodilatation).4 This points to en-
dothelial dysfunction in RVCL-S, which is in line with our 
microvascular and macrovascular observations in the homo-
zygous mutant mice. Although flow-mediated vasodilatation 
responses are generally considered as a measure for macro-
vascular function, it should be kept in mind that flow-medi-
ated vasodilatation is a physiological response to the increased 
shear stress during reactive hyperemia and is thus critically 
dependent on the reactivity of the downstream microvascula-
ture to transient ischemia.
Limitations
As discussed above, our study has several limitations. First, 
we used homozygous RVCL-S KI mice, although RVCL-S 
in humans is caused by the presence of only 1 mutated 
allele, and therefore, translation of the results should be 
done with caution. Second, several pathological features 
seen in RVCL-S in humans (ie, vasculopathy of the retina 
and other organs, microinfarcts, and white matter lesions) 
were not seen during basic examination in our model. In 
future experiments, a more in-depth analysis, for example, 
using electron microscopy, should be done to address this 
point. Furthermore, because of study design, we used surviv-
ing older animals, which probably have a less severe aging 
and disease phenotype. It remains an enigma why experi-
mental stroke outcomes in the oldest animals are less severe.
In conclusion, we found that the homozygous RVCL-S 
KI mice exhibit early mortality in line with the reduced life 
expectancy seen in (heterozygous) patients with RVCL-S. 
Moreover, we observed a blunted (cerebral) microvascular re-
sponse suggestive of endothelial involvement, which seems to 
occur already in young mutant mice, as well as an abnormal 
macrovascular response in old mutants. Finally, we observed 
an increased infarct size and worse outcome in homozygous 
RVCL-S KI mice in response to experimentally induced 
stroke, but it is at present unclear how this relates to the phe-
notype in patients with RVCL-S. Regardless, our RVCL-S KI 
mouse model seems very promising to help unravel the patho-
physiology of RVCL-S.
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